Valeant Files Another Complaint Over ‘False’ Allergan Info

Valeant Pharmaceuticals International Inc. on Thursday filed another complaint, this time with a Canadian regulator, accusing $53 billion takeover target Allergan Inc. of making “false and misleading” statements about Valeant’s business to erode support for the proposed tie-up.